 William Robinson
Concepts (849)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 93 | 2024 | 807 | 6.760 |
Why?
| | Skin Neoplasms | 49 | 2025 | 869 | 3.860 |
Why?
| | Proto-Oncogene Proteins c-kit | 6 | 2019 | 72 | 1.640 |
Why?
| | Mastocytosis | 3 | 2021 | 12 | 1.420 |
Why?
| | Antineoplastic Agents | 19 | 2024 | 2195 | 1.090 |
Why?
| | Spinal Fusion | 4 | 2022 | 260 | 0.900 |
Why?
| | Melanocytes | 7 | 2024 | 66 | 0.860 |
Why?
| | Oncogene Proteins, Fusion | 3 | 2025 | 213 | 0.790 |
Why?
| | Mutation | 17 | 2022 | 4053 | 0.760 |
Why?
| | Vitiligo | 5 | 2024 | 42 | 0.740 |
Why?
| | Antibodies, Monoclonal | 7 | 2018 | 1474 | 0.730 |
Why?
| | Osteoporotic Fractures | 2 | 2020 | 61 | 0.730 |
Why?
| | Thoracic Vertebrae | 2 | 2020 | 78 | 0.720 |
Why?
| | Mucous Membrane | 2 | 2024 | 127 | 0.700 |
Why?
| | Proto-Oncogene Proteins B-raf | 7 | 2025 | 230 | 0.690 |
Why?
| | Mastocytosis, Cutaneous | 1 | 2021 | 5 | 0.680 |
Why?
| | Piperazines | 7 | 2018 | 393 | 0.650 |
Why?
| | Gastrointestinal Stromal Tumors | 2 | 2019 | 39 | 0.640 |
Why?
| | Spinal Fractures | 1 | 2020 | 74 | 0.610 |
Why?
| | Middle Aged | 94 | 2024 | 35342 | 0.600 |
Why?
| | Germ-Line Mutation | 2 | 2019 | 173 | 0.590 |
Why?
| | Exome | 2 | 2017 | 240 | 0.590 |
Why?
| | Esophageal Achalasia | 1 | 2019 | 29 | 0.580 |
Why?
| | Humans | 210 | 2025 | 143560 | 0.580 |
Why?
| | Intervertebral Disc Displacement | 1 | 2019 | 41 | 0.570 |
Why?
| | Neurofibromin 1 | 2 | 2017 | 25 | 0.560 |
Why?
| | Histiocytosis, Sinus | 1 | 2018 | 8 | 0.560 |
Why?
| | Humeral Head | 1 | 2017 | 15 | 0.550 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 5 | 2013 | 90 | 0.550 |
Why?
| | Osteoporosis | 2 | 2020 | 244 | 0.540 |
Why?
| | Carcinoma, Merkel Cell | 2 | 2008 | 15 | 0.530 |
Why?
| | Orthopedics | 1 | 2020 | 156 | 0.530 |
Why?
| | Arthroplasty, Replacement, Shoulder | 1 | 2017 | 34 | 0.530 |
Why?
| | Skin Pigmentation | 4 | 2024 | 48 | 0.520 |
Why?
| | Intention | 1 | 2019 | 181 | 0.510 |
Why?
| | RNA Splicing Factors | 1 | 2017 | 58 | 0.510 |
Why?
| | Myeloid-Derived Suppressor Cells | 3 | 2024 | 72 | 0.510 |
Why?
| | Genetic Predisposition to Disease | 5 | 2019 | 2417 | 0.510 |
Why?
| | Granulocytes | 26 | 1988 | 81 | 0.500 |
Why?
| | Hematopoiesis | 24 | 1988 | 194 | 0.490 |
Why?
| | Databases, Factual | 4 | 2020 | 1465 | 0.490 |
Why?
| | Female | 119 | 2025 | 77251 | 0.490 |
Why?
| | MicroRNAs | 4 | 2023 | 698 | 0.480 |
Why?
| | Forecasting | 2 | 2017 | 384 | 0.480 |
Why?
| | Ultraviolet Therapy | 4 | 2024 | 17 | 0.470 |
Why?
| | Shoulder Joint | 1 | 2017 | 177 | 0.470 |
Why?
| | Sentinel Lymph Node Biopsy | 7 | 2021 | 115 | 0.460 |
Why?
| | Neoplasms, Second Primary | 3 | 2023 | 98 | 0.450 |
Why?
| | Osteoarthritis | 1 | 2017 | 211 | 0.450 |
Why?
| | Adult | 95 | 2025 | 40013 | 0.450 |
Why?
| | Biomarkers, Tumor | 8 | 2019 | 1282 | 0.450 |
Why?
| | Phosphoproteins | 1 | 2017 | 337 | 0.440 |
Why?
| | Male | 101 | 2025 | 71500 | 0.430 |
Why?
| | Pyrimidines | 4 | 2008 | 524 | 0.430 |
Why?
| | Aged | 63 | 2024 | 25322 | 0.420 |
Why?
| | Colony-Stimulating Factors | 20 | 1988 | 37 | 0.410 |
Why?
| | Aged, 80 and over | 21 | 2021 | 8072 | 0.410 |
Why?
| | Microphthalmia-Associated Transcription Factor | 3 | 2008 | 14 | 0.400 |
Why?
| | Nevus | 3 | 2010 | 26 | 0.400 |
Why?
| | Cell Line, Tumor | 18 | 2024 | 3611 | 0.390 |
Why?
| | Neoplastic Stem Cells | 5 | 2018 | 414 | 0.370 |
Why?
| | Milk, Human | 1 | 2014 | 172 | 0.360 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2012 | 39 | 0.360 |
Why?
| | Pyrroles | 3 | 2021 | 210 | 0.350 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 3 | 2024 | 41 | 0.340 |
Why?
| | Triazines | 2 | 2021 | 46 | 0.340 |
Why?
| | Military Personnel | 1 | 2019 | 684 | 0.340 |
Why?
| | Breast Neoplasms | 8 | 2017 | 2318 | 0.330 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 11 | 2023 | 1827 | 0.330 |
Why?
| | Gastrointestinal Neoplasms | 2 | 2008 | 75 | 0.320 |
Why?
| | Lymph Node Excision | 5 | 2021 | 170 | 0.320 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2018 | 1487 | 0.320 |
Why?
| | Sentinel Lymph Node | 2 | 2021 | 46 | 0.320 |
Why?
| | Lymphatic Metastasis | 7 | 2013 | 328 | 0.320 |
Why?
| | Sulfonamides | 4 | 2020 | 582 | 0.320 |
Why?
| | Genes, p16 | 3 | 2007 | 14 | 0.310 |
Why?
| | Adenocarcinoma | 5 | 2016 | 911 | 0.310 |
Why?
| | Lumbar Vertebrae | 3 | 2022 | 252 | 0.300 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2018 | 549 | 0.290 |
Why?
| | RNA, Neoplasm | 2 | 2008 | 83 | 0.290 |
Why?
| | Immunohistochemistry | 6 | 2019 | 1736 | 0.290 |
Why?
| | Leukocytes | 14 | 1986 | 299 | 0.290 |
Why?
| | Lumbosacral Region | 2 | 2019 | 62 | 0.290 |
Why?
| | Sarcoma, Clear Cell | 1 | 2008 | 9 | 0.280 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2022 | 194 | 0.280 |
Why?
| | Tumor Suppressor Proteins | 4 | 2024 | 330 | 0.280 |
Why?
| | Treatment Outcome | 15 | 2022 | 11365 | 0.280 |
Why?
| | Lymphoma, Mantle-Cell | 1 | 2008 | 30 | 0.280 |
Why?
| | Cyclins | 1 | 2008 | 101 | 0.270 |
Why?
| | Proto-Oncogene Proteins | 3 | 2018 | 626 | 0.270 |
Why?
| | Nitrophenols | 3 | 2017 | 32 | 0.270 |
Why?
| | Quality Improvement | 2 | 2018 | 1263 | 0.270 |
Why?
| | Tretinoin | 4 | 2023 | 124 | 0.270 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2008 | 47 | 0.270 |
Why?
| | Pyrazoles | 2 | 2021 | 496 | 0.260 |
Why?
| | Biphenyl Compounds | 3 | 2017 | 70 | 0.260 |
Why?
| | Tamoxifen | 3 | 2016 | 204 | 0.260 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2018 | 341 | 0.260 |
Why?
| | Prognosis | 14 | 2024 | 4152 | 0.250 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2007 | 43 | 0.250 |
Why?
| | GTP Phosphohydrolases | 4 | 2020 | 96 | 0.240 |
Why?
| | Interferon-alpha | 6 | 2006 | 197 | 0.240 |
Why?
| | Hair Color | 2 | 2024 | 15 | 0.230 |
Why?
| | Arthroplasty, Replacement, Knee | 2 | 2022 | 373 | 0.230 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 5 | 2021 | 245 | 0.230 |
Why?
| | Nevus, Pigmented | 1 | 2025 | 35 | 0.230 |
Why?
| | DNA, Neoplasm | 5 | 2017 | 162 | 0.230 |
Why?
| | Liposarcoma | 1 | 2005 | 30 | 0.220 |
Why?
| | Epidermis | 2 | 2024 | 159 | 0.220 |
Why?
| | Xenograft Model Antitumor Assays | 6 | 2018 | 941 | 0.220 |
Why?
| | Follow-Up Studies | 12 | 2020 | 5308 | 0.220 |
Why?
| | Intestinal Neoplasms | 1 | 2024 | 31 | 0.220 |
Why?
| | T-Lymphocytes, Regulatory | 3 | 2023 | 395 | 0.220 |
Why?
| | Intestine, Small | 2 | 2024 | 159 | 0.220 |
Why?
| | Polymerase Chain Reaction | 6 | 2008 | 1062 | 0.210 |
Why?
| | Dasatinib | 1 | 2024 | 59 | 0.210 |
Why?
| | Hyperpigmentation | 1 | 2024 | 27 | 0.210 |
Why?
| | Ultraviolet Rays | 4 | 2024 | 401 | 0.210 |
Why?
| | Piperidines | 2 | 2018 | 224 | 0.210 |
Why?
| | Lymph Nodes | 1 | 2006 | 499 | 0.210 |
Why?
| | Dacarbazine | 7 | 2012 | 97 | 0.200 |
Why?
| | Hair Follicle | 3 | 2020 | 48 | 0.200 |
Why?
| | Neoplasm Staging | 10 | 2019 | 1416 | 0.200 |
Why?
| | Mice | 28 | 2024 | 18378 | 0.200 |
Why?
| | Mice, Nude | 4 | 2020 | 710 | 0.200 |
Why?
| | Genomics | 4 | 2024 | 831 | 0.200 |
Why?
| | Exons | 3 | 2019 | 359 | 0.200 |
Why?
| | Melatonin | 3 | 1994 | 163 | 0.200 |
Why?
| | Stem Cells | 4 | 2017 | 619 | 0.200 |
Why?
| | Burns | 7 | 1997 | 360 | 0.200 |
Why?
| | HLA-DR Antigens | 2 | 2022 | 223 | 0.190 |
Why?
| | Genes, erbB-1 | 2 | 2016 | 18 | 0.190 |
Why?
| | Flavonoids | 1 | 2003 | 88 | 0.190 |
Why?
| | Lysophospholipids | 1 | 2023 | 75 | 0.190 |
Why?
| | Chromosome Aberrations | 2 | 1994 | 164 | 0.190 |
Why?
| | Pedigree | 3 | 2024 | 513 | 0.190 |
Why?
| | Cervical Vertebrae | 2 | 2021 | 150 | 0.190 |
Why?
| | Retrospective Studies | 17 | 2025 | 16741 | 0.180 |
Why?
| | Drug Resistance, Neoplasm | 6 | 2016 | 875 | 0.180 |
Why?
| | Molecular Targeted Therapy | 3 | 2024 | 431 | 0.180 |
Why?
| | Lordosis | 1 | 2022 | 16 | 0.180 |
Why?
| | Colonic Neoplasms | 1 | 2024 | 259 | 0.180 |
Why?
| | Spondylolisthesis | 1 | 2021 | 8 | 0.180 |
Why?
| | Hematopoietic Stem Cells | 11 | 1986 | 417 | 0.180 |
Why?
| | Mastocytosis, Systemic | 1 | 2021 | 8 | 0.180 |
Why?
| | Clone Cells | 7 | 2010 | 270 | 0.180 |
Why?
| | Spinal Cord Diseases | 1 | 2021 | 44 | 0.180 |
Why?
| | Neoplasm Recurrence, Local | 9 | 2016 | 1095 | 0.170 |
Why?
| | Registries | 3 | 2020 | 2238 | 0.170 |
Why?
| | Cell Cycle Proteins | 3 | 2007 | 651 | 0.170 |
Why?
| | Risk Factors | 8 | 2020 | 10644 | 0.170 |
Why?
| | Interleukin-1 | 2 | 2019 | 970 | 0.160 |
Why?
| | Gene Expression Profiling | 5 | 2024 | 1794 | 0.160 |
Why?
| | Sonication | 1 | 2020 | 12 | 0.160 |
Why?
| | Drug Therapy, Combination | 5 | 2016 | 1058 | 0.160 |
Why?
| | Animals | 34 | 2024 | 38010 | 0.160 |
Why?
| | Adult Stem Cells | 1 | 2020 | 40 | 0.160 |
Why?
| | Leukemia | 8 | 1988 | 245 | 0.160 |
Why?
| | Laser Capture Microdissection | 2 | 2017 | 31 | 0.160 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2024 | 928 | 0.160 |
Why?
| | Tissue Culture Techniques | 1 | 2020 | 82 | 0.160 |
Why?
| | Turner Syndrome | 1 | 2001 | 65 | 0.160 |
Why?
| | Transcription, Genetic | 5 | 2017 | 1511 | 0.160 |
Why?
| | Arthroplasty, Replacement, Finger | 1 | 2019 | 3 | 0.150 |
Why?
| | Finger Joint | 1 | 2019 | 10 | 0.150 |
Why?
| | Tumor Cells, Cultured | 6 | 2003 | 974 | 0.150 |
Why?
| | Aniline Compounds | 1 | 2020 | 120 | 0.150 |
Why?
| | Finger Phalanges | 1 | 2019 | 13 | 0.150 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2019 | 75 | 0.150 |
Why?
| | beta Catenin | 2 | 2020 | 256 | 0.150 |
Why?
| | Heart Neoplasms | 2 | 1999 | 55 | 0.150 |
Why?
| | Prosthesis-Related Infections | 1 | 2020 | 98 | 0.150 |
Why?
| | Nomograms | 1 | 2019 | 58 | 0.150 |
Why?
| | Sequence Analysis, RNA | 3 | 2018 | 447 | 0.150 |
Why?
| | Visual Analog Scale | 1 | 2019 | 35 | 0.150 |
Why?
| | RNA | 2 | 2016 | 933 | 0.150 |
Why?
| | Bone Density | 2 | 2020 | 503 | 0.150 |
Why?
| | Prostheses and Implants | 1 | 2020 | 145 | 0.150 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2018 | 38 | 0.140 |
Why?
| | CDC2 Protein Kinase | 1 | 2018 | 32 | 0.140 |
Why?
| | Intervertebral Disc Degeneration | 1 | 2019 | 33 | 0.140 |
Why?
| | Signal Transduction | 7 | 2023 | 5214 | 0.140 |
Why?
| | Reoperation | 2 | 2019 | 605 | 0.140 |
Why?
| | Ipilimumab | 1 | 2018 | 41 | 0.140 |
Why?
| | SOXB1 Transcription Factors | 1 | 2018 | 66 | 0.140 |
Why?
| | Septins | 1 | 2018 | 43 | 0.140 |
Why?
| | Hospital Costs | 1 | 2018 | 123 | 0.140 |
Why?
| | Case-Control Studies | 5 | 2022 | 3625 | 0.140 |
Why?
| | Leukemia, Myeloid | 10 | 1984 | 48 | 0.140 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2017 | 26 | 0.140 |
Why?
| | Colony-Forming Units Assay | 19 | 1988 | 94 | 0.130 |
Why?
| | Imatinib Mesylate | 2 | 2008 | 80 | 0.130 |
Why?
| | Receptors, Androgen | 1 | 1998 | 155 | 0.130 |
Why?
| | Biofilms | 1 | 2020 | 278 | 0.130 |
Why?
| | Bone Marrow Cells | 17 | 1983 | 319 | 0.130 |
Why?
| | Adolescent | 35 | 2025 | 22481 | 0.130 |
Why?
| | Burns, Electric | 3 | 1986 | 26 | 0.130 |
Why?
| | Microtubule-Associated Proteins | 1 | 2018 | 201 | 0.130 |
Why?
| | Low Back Pain | 1 | 2019 | 109 | 0.130 |
Why?
| | Bone Marrow | 14 | 1983 | 301 | 0.130 |
Why?
| | Databases, Genetic | 1 | 2018 | 248 | 0.130 |
Why?
| | Secondary Prevention | 1 | 2018 | 241 | 0.130 |
Why?
| | Cisplatin | 4 | 2006 | 333 | 0.130 |
Why?
| | Cancer-Associated Fibroblasts | 1 | 2016 | 25 | 0.120 |
Why?
| | Freezing | 4 | 2014 | 88 | 0.120 |
Why?
| | Benzamides | 2 | 2008 | 223 | 0.120 |
Why?
| | Preservation, Biological | 3 | 2014 | 7 | 0.120 |
Why?
| | Membrane Proteins | 4 | 2020 | 1171 | 0.120 |
Why?
| | Bone Marrow Transplantation | 10 | 1986 | 292 | 0.120 |
Why?
| | Pain Measurement | 1 | 2019 | 558 | 0.120 |
Why?
| | Apoptosis | 4 | 2018 | 2519 | 0.120 |
Why?
| | Carrier Proteins | 2 | 2000 | 752 | 0.120 |
Why?
| | Mitochondrial Proteins | 1 | 2018 | 262 | 0.120 |
Why?
| | Genes, Tumor Suppressor | 1 | 1996 | 92 | 0.120 |
Why?
| | Adenine | 1 | 2018 | 337 | 0.120 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 1994 | 125 | 0.120 |
Why?
| | Drug Synergism | 4 | 2018 | 370 | 0.120 |
Why?
| | Protein Isoforms | 1 | 2017 | 404 | 0.120 |
Why?
| | Interferon Type I | 4 | 1994 | 141 | 0.120 |
Why?
| | Lentigo | 1 | 2015 | 6 | 0.120 |
Why?
| | Aldehyde Dehydrogenase | 2 | 2014 | 100 | 0.120 |
Why?
| | Lung Neoplasms | 7 | 2016 | 2580 | 0.120 |
Why?
| | Antigens, Neoplasm | 5 | 2005 | 324 | 0.120 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 5 | 2011 | 994 | 0.110 |
Why?
| | Brain Neoplasms | 4 | 1994 | 1300 | 0.110 |
Why?
| | Radiography | 1 | 2017 | 846 | 0.110 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1292 | 0.110 |
Why?
| | Neoplastic Cells, Circulating | 2 | 2006 | 80 | 0.110 |
Why?
| | Leukocyte Count | 20 | 1988 | 317 | 0.110 |
Why?
| | Myeloproliferative Disorders | 1 | 1995 | 27 | 0.110 |
Why?
| | Cell Cycle | 3 | 2010 | 648 | 0.110 |
Why?
| | Fenretinide | 1 | 2014 | 4 | 0.110 |
Why?
| | Head and Neck Neoplasms | 3 | 2013 | 562 | 0.110 |
Why?
| | Oligopeptides | 1 | 2016 | 266 | 0.110 |
Why?
| | Desiccation | 1 | 2014 | 22 | 0.110 |
Why?
| | Survival Analysis | 6 | 2010 | 1332 | 0.110 |
Why?
| | Lymphoma | 4 | 1991 | 228 | 0.110 |
Why?
| | Cell Division | 11 | 1998 | 806 | 0.110 |
Why?
| | Cell Survival | 8 | 2018 | 1136 | 0.110 |
Why?
| | Peptide Fragments | 1 | 2018 | 698 | 0.110 |
Why?
| | Survival Rate | 8 | 2024 | 2003 | 0.110 |
Why?
| | Peptides | 2 | 2008 | 976 | 0.110 |
Why?
| | Cohort Studies | 3 | 2024 | 5891 | 0.100 |
Why?
| | Perineum | 1 | 1993 | 38 | 0.100 |
Why?
| | Child | 17 | 2025 | 22725 | 0.100 |
Why?
| | Receptors, Estrogen | 1 | 2016 | 425 | 0.100 |
Why?
| | Basigin | 1 | 2013 | 24 | 0.100 |
Why?
| | Ear, External | 1 | 2013 | 22 | 0.100 |
Why?
| | Mohs Surgery | 1 | 2013 | 29 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 7 | 2021 | 2056 | 0.100 |
Why?
| | Internet | 1 | 2018 | 698 | 0.100 |
Why?
| | Extracellular Space | 1 | 2013 | 129 | 0.100 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 1992 | 55 | 0.100 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2013 | 138 | 0.100 |
Why?
| | Sweat Gland Neoplasms | 1 | 2012 | 8 | 0.100 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2017 | 317 | 0.100 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 1992 | 60 | 0.100 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2023 | 927 | 0.100 |
Why?
| | Cell Proliferation | 5 | 2018 | 2542 | 0.100 |
Why?
| | Side-Population Cells | 1 | 2012 | 8 | 0.090 |
Why?
| | BRCA1 Protein | 1 | 2013 | 79 | 0.090 |
Why?
| | Alcohol Oxidoreductases | 1 | 2013 | 63 | 0.090 |
Why?
| | Vitamins | 1 | 1994 | 181 | 0.090 |
Why?
| | Alleles | 2 | 2022 | 893 | 0.090 |
Why?
| | Bone Marrow Diseases | 3 | 1983 | 21 | 0.090 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2013 | 169 | 0.090 |
Why?
| | Ricin | 1 | 1991 | 8 | 0.090 |
Why?
| | Decision Making | 1 | 2019 | 962 | 0.090 |
Why?
| | Pyrimidinones | 2 | 2025 | 127 | 0.090 |
Why?
| | Escherichia coli Infections | 4 | 1981 | 119 | 0.090 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2013 | 647 | 0.090 |
Why?
| | Sequence Analysis, DNA | 2 | 2005 | 823 | 0.090 |
Why?
| | Peer Review | 1 | 2012 | 46 | 0.090 |
Why?
| | Immunotoxins | 1 | 1991 | 55 | 0.090 |
Why?
| | DNA Mutational Analysis | 2 | 2016 | 404 | 0.090 |
Why?
| | Severity of Illness Index | 2 | 2018 | 2936 | 0.090 |
Why?
| | Malpractice | 1 | 2012 | 45 | 0.090 |
Why?
| | Phenotype | 5 | 2024 | 3211 | 0.090 |
Why?
| | Complement C1q | 1 | 2011 | 33 | 0.090 |
Why?
| | History, 21st Century | 1 | 2012 | 220 | 0.080 |
Why?
| | Keratinocytes | 2 | 2024 | 253 | 0.080 |
Why?
| | Immune Tolerance | 2 | 1991 | 381 | 0.080 |
Why?
| | Agranulocytosis | 6 | 1986 | 30 | 0.080 |
Why?
| | United States | 3 | 2020 | 15553 | 0.080 |
Why?
| | History, 20th Century | 1 | 2012 | 327 | 0.080 |
Why?
| | Pancreatitis | 1 | 1991 | 136 | 0.080 |
Why?
| | Cyclosporine | 1 | 1991 | 266 | 0.080 |
Why?
| | Blast Crisis | 1 | 1990 | 34 | 0.080 |
Why?
| | Predictive Value of Tests | 2 | 2006 | 2086 | 0.080 |
Why?
| | Time Factors | 15 | 2019 | 7031 | 0.080 |
Why?
| | Risk Assessment | 1 | 2019 | 3577 | 0.080 |
Why?
| | Bacterial Infections | 4 | 1989 | 246 | 0.080 |
Why?
| | Urinary Bladder Neoplasms | 2 | 1983 | 261 | 0.080 |
Why?
| | Vitamin E | 2 | 1994 | 123 | 0.080 |
Why?
| | Glycoproteins | 5 | 1977 | 356 | 0.080 |
Why?
| | Disease-Free Survival | 5 | 2019 | 720 | 0.080 |
Why?
| | Neoplasms | 5 | 2018 | 2804 | 0.080 |
Why?
| | Indium Radioisotopes | 1 | 1989 | 12 | 0.080 |
Why?
| | Cells, Cultured | 12 | 2019 | 4182 | 0.080 |
Why?
| | Recombinant Proteins | 7 | 1994 | 1369 | 0.080 |
Why?
| | Interleukin-6 | 1 | 2013 | 781 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 2 | 2018 | 2779 | 0.070 |
Why?
| | Osteonecrosis | 2 | 1986 | 25 | 0.070 |
Why?
| | Transforming Growth Factor beta | 3 | 2019 | 484 | 0.070 |
Why?
| | Cell Differentiation | 7 | 2015 | 2020 | 0.070 |
Why?
| | Neutrophils | 8 | 1988 | 1134 | 0.070 |
Why?
| | Lithium | 5 | 1986 | 42 | 0.070 |
Why?
| | Cyclin D | 1 | 2008 | 11 | 0.070 |
Why?
| | ErbB Receptors | 2 | 2013 | 617 | 0.070 |
Why?
| | Base Sequence | 2 | 2011 | 2199 | 0.070 |
Why?
| | Surgical Flaps | 3 | 1986 | 145 | 0.070 |
Why?
| | Lymphocytes | 7 | 2006 | 398 | 0.070 |
Why?
| | Inflammation | 1 | 2019 | 2881 | 0.070 |
Why?
| | Risk | 2 | 2019 | 906 | 0.070 |
Why?
| | Transcription Factors | 1 | 1996 | 1754 | 0.070 |
Why?
| | Patient Safety | 1 | 2012 | 340 | 0.070 |
Why?
| | S Phase | 1 | 2008 | 89 | 0.070 |
Why?
| | Up-Regulation | 3 | 2019 | 863 | 0.070 |
Why?
| | Skull | 2 | 1986 | 152 | 0.070 |
Why?
| | Glucuronidase | 1 | 2007 | 26 | 0.070 |
Why?
| | Sequence Deletion | 1 | 2008 | 193 | 0.070 |
Why?
| | Receptor, Notch2 | 2 | 2020 | 15 | 0.070 |
Why?
| | Australia | 2 | 2023 | 290 | 0.070 |
Why?
| | Li-Fraumeni Syndrome | 1 | 2007 | 14 | 0.070 |
Why?
| | Computational Biology | 3 | 2019 | 677 | 0.070 |
Why?
| | 3' Untranslated Regions | 1 | 2008 | 153 | 0.070 |
Why?
| | Oligosaccharides | 1 | 2007 | 60 | 0.070 |
Why?
| | Receptor, Melanocortin, Type 1 | 1 | 2007 | 7 | 0.060 |
Why?
| | Cell Movement | 5 | 2015 | 973 | 0.060 |
Why?
| | Paraneoplastic Syndromes | 1 | 2007 | 12 | 0.060 |
Why?
| | Factor VIII | 1 | 1987 | 103 | 0.060 |
Why?
| | Adjuvants, Immunologic | 1 | 2008 | 240 | 0.060 |
Why?
| | Cell Self Renewal | 2 | 2017 | 55 | 0.060 |
Why?
| | Chromosome Mapping | 1 | 2008 | 517 | 0.060 |
Why?
| | Vaccinia virus | 2 | 1998 | 44 | 0.060 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2010 | 539 | 0.060 |
Why?
| | Education, Medical | 1 | 1990 | 276 | 0.060 |
Why?
| | Myelodysplastic Syndromes | 1 | 1988 | 143 | 0.060 |
Why?
| | Disease Progression | 2 | 2013 | 2856 | 0.060 |
Why?
| | Health Education | 1 | 1990 | 363 | 0.060 |
Why?
| | Quinazolines | 1 | 2008 | 261 | 0.060 |
Why?
| | Binding Sites | 2 | 2008 | 1325 | 0.060 |
Why?
| | Enterobacteriaceae | 1 | 2006 | 43 | 0.060 |
Why?
| | Colony Count, Microbial | 1 | 2006 | 124 | 0.060 |
Why?
| | Young Adult | 5 | 2025 | 13972 | 0.060 |
Why?
| | Neoadjuvant Therapy | 2 | 2006 | 438 | 0.060 |
Why?
| | Models, Biological | 4 | 2019 | 1831 | 0.060 |
Why?
| | Vena Cava, Superior | 1 | 1985 | 24 | 0.060 |
Why?
| | Hypercalcemia | 1 | 1985 | 23 | 0.060 |
Why?
| | Spinal Cord Compression | 1 | 1985 | 22 | 0.060 |
Why?
| | Water Microbiology | 1 | 2006 | 89 | 0.060 |
Why?
| | Fasciotomy | 1 | 1985 | 23 | 0.060 |
Why?
| | Genome, Human | 1 | 2008 | 429 | 0.060 |
Why?
| | Viral Vaccines | 2 | 1998 | 107 | 0.060 |
Why?
| | PTEN Phosphohydrolase | 1 | 2007 | 165 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3798 | 0.060 |
Why?
| | Hemophilia A | 1 | 1987 | 146 | 0.060 |
Why?
| | Forearm Injuries | 1 | 1985 | 7 | 0.060 |
Why?
| | Diphosphonates | 1 | 2006 | 70 | 0.060 |
Why?
| | Chromates | 1 | 1985 | 2 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 1 | 2008 | 589 | 0.060 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2005 | 22 | 0.060 |
Why?
| | Pruritus | 1 | 2025 | 64 | 0.060 |
Why?
| | In Vitro Techniques | 5 | 2012 | 1064 | 0.060 |
Why?
| | DNA-Binding Proteins | 1 | 2013 | 1524 | 0.060 |
Why?
| | Chromium | 1 | 1985 | 17 | 0.060 |
Why?
| | Testicular Neoplasms | 2 | 1984 | 115 | 0.060 |
Why?
| | Neoplasm Invasiveness | 3 | 2018 | 518 | 0.060 |
Why?
| | Karyotyping | 4 | 1994 | 106 | 0.060 |
Why?
| | Kidney Transplantation | 1 | 1991 | 698 | 0.060 |
Why?
| | Forearm | 1 | 1985 | 139 | 0.060 |
Why?
| | Wrist | 1 | 1985 | 58 | 0.060 |
Why?
| | Hand Injuries | 1 | 1985 | 32 | 0.060 |
Why?
| | Axilla | 1 | 2004 | 48 | 0.060 |
Why?
| | Infant | 2 | 2019 | 9981 | 0.060 |
Why?
| | Burns, Chemical | 1 | 1985 | 32 | 0.050 |
Why?
| | Skin Transplantation | 1 | 1985 | 85 | 0.050 |
Why?
| | Macrophages | 4 | 1988 | 1506 | 0.050 |
Why?
| | Acute Disease | 6 | 1991 | 1015 | 0.050 |
Why?
| | Protein Transport | 2 | 2018 | 447 | 0.050 |
Why?
| | Immunoenzyme Techniques | 1 | 2004 | 206 | 0.050 |
Why?
| | Ki-67 Antigen | 1 | 2004 | 114 | 0.050 |
Why?
| | Blood Cell Count | 5 | 1995 | 52 | 0.050 |
Why?
| | Monocytes | 5 | 1983 | 545 | 0.050 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2024 | 11 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2012 | 2177 | 0.050 |
Why?
| | Phosphorylation | 2 | 2018 | 1781 | 0.050 |
Why?
| | Neoplasm Metastasis | 4 | 2007 | 682 | 0.050 |
Why?
| | Azepines | 1 | 2024 | 100 | 0.050 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2004 | 61 | 0.050 |
Why?
| | Immunotherapy, Adoptive | 2 | 1998 | 372 | 0.050 |
Why?
| | Genetic Testing | 1 | 2007 | 474 | 0.050 |
Why?
| | Pyridones | 1 | 2025 | 198 | 0.050 |
Why?
| | Age Distribution | 2 | 2018 | 398 | 0.050 |
Why?
| | Urine | 4 | 1973 | 62 | 0.050 |
Why?
| | Monitoring, Immunologic | 1 | 2023 | 23 | 0.050 |
Why?
| | Escherichia coli | 3 | 2006 | 834 | 0.050 |
Why?
| | Molecular Sequence Data | 1 | 2008 | 2942 | 0.050 |
Why?
| | Inhibitory Concentration 50 | 1 | 2003 | 91 | 0.050 |
Why?
| | Schistosoma | 1 | 1983 | 28 | 0.050 |
Why?
| | Receptors, Lysophosphatidic Acid | 1 | 2023 | 35 | 0.050 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2003 | 108 | 0.050 |
Why?
| | Carcinoma, Transitional Cell | 1 | 1983 | 72 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 168 | 0.050 |
Why?
| | Neutropenia | 3 | 1980 | 152 | 0.050 |
Why?
| | Immunity, Cellular | 1 | 1984 | 267 | 0.050 |
Why?
| | Multiple Sclerosis | 1 | 2008 | 483 | 0.050 |
Why?
| | CTLA-4 Antigen | 1 | 2023 | 105 | 0.050 |
Why?
| | Smoking | 1 | 1990 | 1580 | 0.050 |
Why?
| | Receptors, Melanocortin | 1 | 2002 | 1 | 0.050 |
Why?
| | Receptors, Corticotropin | 1 | 2002 | 3 | 0.050 |
Why?
| | Vitamin A | 1 | 1982 | 56 | 0.050 |
Why?
| | Protein Kinase Inhibitors | 2 | 2019 | 963 | 0.050 |
Why?
| | Genes, cdc | 1 | 2002 | 11 | 0.050 |
Why?
| | Cell Lineage | 1 | 2024 | 368 | 0.050 |
Why?
| | Uveal Neoplasms | 1 | 2021 | 17 | 0.050 |
Why?
| | Diskectomy | 1 | 2021 | 25 | 0.040 |
Why?
| | Neck Pain | 1 | 2021 | 27 | 0.040 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2021 | 51 | 0.040 |
Why?
| | Wnt Signaling Pathway | 1 | 2024 | 213 | 0.040 |
Why?
| | Leukocytosis | 4 | 1974 | 33 | 0.040 |
Why?
| | Clinical Trials as Topic | 4 | 2018 | 1043 | 0.040 |
Why?
| | Antigens | 2 | 1983 | 350 | 0.040 |
Why?
| | Gene Expression | 3 | 2008 | 1505 | 0.040 |
Why?
| | Isotretinoin | 2 | 1994 | 25 | 0.040 |
Why?
| | Incidence | 3 | 2009 | 2844 | 0.040 |
Why?
| | PAX3 Transcription Factor | 2 | 2015 | 17 | 0.040 |
Why?
| | Paired Box Transcription Factors | 2 | 2015 | 43 | 0.040 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2002 | 85 | 0.040 |
Why?
| | Bone Neoplasms | 1 | 1983 | 249 | 0.040 |
Why?
| | Disease Models, Animal | 3 | 2018 | 4522 | 0.040 |
Why?
| | Smallpox Vaccine | 2 | 1998 | 24 | 0.040 |
Why?
| | Postoperative Period | 1 | 2022 | 361 | 0.040 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2002 | 147 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p15 | 2 | 2000 | 16 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2003 | 550 | 0.040 |
Why?
| | Administration, Oral | 5 | 1995 | 842 | 0.040 |
Why?
| | Leukemia, Lymphoid | 6 | 1979 | 27 | 0.040 |
Why?
| | Mycobacterium chelonae | 1 | 2020 | 9 | 0.040 |
Why?
| | Enterobacter cloacae | 1 | 2020 | 5 | 0.040 |
Why?
| | Eosinophils | 1 | 1983 | 325 | 0.040 |
Why?
| | Gene Amplification | 1 | 2020 | 108 | 0.040 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2020 | 54 | 0.040 |
Why?
| | Tetracycline | 1 | 2000 | 14 | 0.040 |
Why?
| | Leukemia, Myeloid, Acute | 4 | 1984 | 661 | 0.040 |
Why?
| | Oxidoreductases | 1 | 2020 | 95 | 0.040 |
Why?
| | rho GTP-Binding Proteins | 1 | 2020 | 56 | 0.040 |
Why?
| | Tocopherols | 2 | 1994 | 26 | 0.040 |
Why?
| | Chromosomes, Human, 6-12 and X | 2 | 1994 | 3 | 0.040 |
Why?
| | Gene Dosage | 1 | 2020 | 149 | 0.040 |
Why?
| | Endotoxins | 2 | 1978 | 213 | 0.040 |
Why?
| | Age Factors | 4 | 2019 | 3328 | 0.040 |
Why?
| | Germ-Free Life | 1 | 1979 | 33 | 0.040 |
Why?
| | Data Curation | 1 | 2019 | 19 | 0.040 |
Why?
| | Quality of Life | 2 | 2022 | 3080 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2003 | 839 | 0.040 |
Why?
| | Whole Genome Sequencing | 1 | 2020 | 180 | 0.040 |
Why?
| | Joint Prosthesis | 1 | 2019 | 22 | 0.040 |
Why?
| | RNA, Messenger | 3 | 2019 | 2852 | 0.040 |
Why?
| | Carotenoids | 2 | 1994 | 42 | 0.040 |
Why?
| | Vincristine | 3 | 1984 | 135 | 0.040 |
Why?
| | Aneuploidy | 2 | 1994 | 89 | 0.040 |
Why?
| | Cyclophosphamide | 3 | 1983 | 259 | 0.040 |
Why?
| | Finger Injuries | 1 | 2019 | 26 | 0.040 |
Why?
| | Dysplastic Nevus Syndrome | 1 | 1998 | 2 | 0.040 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2008 | 1133 | 0.040 |
Why?
| | Injections, Subcutaneous | 5 | 2007 | 165 | 0.040 |
Why?
| | Azetidines | 1 | 2018 | 47 | 0.040 |
Why?
| | Dynamins | 1 | 2018 | 38 | 0.040 |
Why?
| | Erythropoietin | 3 | 1982 | 99 | 0.040 |
Why?
| | Mast Cells | 1 | 2020 | 151 | 0.040 |
Why?
| | Oncostatin M | 1 | 1998 | 6 | 0.040 |
Why?
| | Arthritis | 1 | 2019 | 101 | 0.040 |
Why?
| | Prosthesis Failure | 1 | 2019 | 125 | 0.040 |
Why?
| | Heterografts | 1 | 2018 | 138 | 0.030 |
Why?
| | Chromosome Deletion | 2 | 1994 | 124 | 0.030 |
Why?
| | Echocardiography, Transesophageal | 1 | 1999 | 131 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2020 | 498 | 0.030 |
Why?
| | Levamisole | 1 | 1977 | 20 | 0.030 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2018 | 188 | 0.030 |
Why?
| | Drug Approval | 1 | 2018 | 89 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2019 | 377 | 0.030 |
Why?
| | Bcl-2-Like Protein 11 | 1 | 2017 | 38 | 0.030 |
Why?
| | Bone Density Conservation Agents | 1 | 2018 | 83 | 0.030 |
Why?
| | Drug Utilization | 1 | 2018 | 166 | 0.030 |
Why?
| | Sex Distribution | 1 | 2018 | 383 | 0.030 |
Why?
| | Drug Evaluation | 4 | 1991 | 79 | 0.030 |
Why?
| | Precancerous Conditions | 1 | 1998 | 165 | 0.030 |
Why?
| | Felty Syndrome | 4 | 1980 | 4 | 0.030 |
Why?
| | Gene Knockout Techniques | 1 | 2017 | 117 | 0.030 |
Why?
| | Skilled Nursing Facilities | 1 | 2018 | 149 | 0.030 |
Why?
| | Pharmacogenetics | 1 | 2018 | 167 | 0.030 |
Why?
| | Range of Motion, Articular | 1 | 2019 | 415 | 0.030 |
Why?
| | Genes, p53 | 1 | 1997 | 68 | 0.030 |
Why?
| | Thioguanine | 2 | 1984 | 18 | 0.030 |
Why?
| | Carmustine | 3 | 1986 | 51 | 0.030 |
Why?
| | CD146 Antigen | 1 | 2016 | 42 | 0.030 |
Why?
| | Menopause | 2 | 2006 | 317 | 0.030 |
Why?
| | Cytarabine | 2 | 1984 | 65 | 0.030 |
Why?
| | MCF-7 Cells | 1 | 2016 | 130 | 0.030 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2016 | 78 | 0.030 |
Why?
| | Thrombocytopenia | 4 | 2007 | 209 | 0.030 |
Why?
| | Cicatrix | 1 | 1997 | 70 | 0.030 |
Why?
| | Splenomegaly | 2 | 1995 | 15 | 0.030 |
Why?
| | Vinblastine | 2 | 2006 | 72 | 0.030 |
Why?
| | Combined Modality Therapy | 3 | 1998 | 1252 | 0.030 |
Why?
| | Cancer Vaccines | 1 | 1997 | 166 | 0.030 |
Why?
| | Hodgkin Disease | 4 | 1985 | 159 | 0.030 |
Why?
| | Interleukin-2 | 3 | 2006 | 451 | 0.030 |
Why?
| | Drug Administration Schedule | 4 | 2007 | 773 | 0.030 |
Why?
| | Prostatic Neoplasms | 1 | 2003 | 1058 | 0.030 |
Why?
| | Mercaptopurine | 2 | 1972 | 15 | 0.030 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2016 | 173 | 0.030 |
Why?
| | Lymphatic Diseases | 1 | 1995 | 22 | 0.030 |
Why?
| | Gene Deletion | 1 | 1997 | 394 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2016 | 183 | 0.030 |
Why?
| | Anesthesia | 1 | 2018 | 251 | 0.030 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2015 | 66 | 0.030 |
Why?
| | Veins | 1 | 1995 | 70 | 0.030 |
Why?
| | Polycythemia Vera | 1 | 1974 | 11 | 0.030 |
Why?
| | Primary Myelofibrosis | 1 | 1974 | 11 | 0.030 |
Why?
| | Infusions, Intravenous | 2 | 1995 | 423 | 0.030 |
Why?
| | Genetic Linkage | 1 | 2015 | 288 | 0.030 |
Why?
| | Retinoids | 1 | 2014 | 34 | 0.030 |
Why?
| | Protein Binding | 2 | 2018 | 2261 | 0.030 |
Why?
| | Culture Techniques | 4 | 1979 | 74 | 0.030 |
Why?
| | Random Allocation | 3 | 1990 | 370 | 0.030 |
Why?
| | Inpatients | 1 | 2018 | 521 | 0.030 |
Why?
| | Proteinuria | 1 | 1974 | 99 | 0.030 |
Why?
| | Chromosomes, Human, 16-18 | 1 | 1994 | 3 | 0.030 |
Why?
| | beta Carotene | 1 | 1994 | 20 | 0.030 |
Why?
| | Chromosomes, Human, Pair 13 | 1 | 1994 | 16 | 0.030 |
Why?
| | Surgeons | 1 | 2018 | 336 | 0.030 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 1994 | 29 | 0.030 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 1994 | 46 | 0.030 |
Why?
| | Vaginal Neoplasms | 1 | 1993 | 19 | 0.030 |
Why?
| | Vulvar Neoplasms | 1 | 1993 | 13 | 0.030 |
Why?
| | Vitamin B 12 | 1 | 1974 | 125 | 0.030 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 1994 | 42 | 0.030 |
Why?
| | Estrogens | 1 | 2016 | 372 | 0.030 |
Why?
| | Anus Neoplasms | 1 | 1993 | 33 | 0.030 |
Why?
| | Catheterization, Central Venous | 1 | 1995 | 117 | 0.030 |
Why?
| | Administration, Intranasal | 3 | 1989 | 94 | 0.020 |
Why?
| | Translocation, Genetic | 1 | 1994 | 109 | 0.020 |
Why?
| | Gonanes | 1 | 2013 | 27 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 1994 | 321 | 0.020 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 1994 | 197 | 0.020 |
Why?
| | Feedback, Physiological | 1 | 2013 | 81 | 0.020 |
Why?
| | Specimen Handling | 1 | 2014 | 181 | 0.020 |
Why?
| | Alphapapillomavirus | 1 | 2013 | 38 | 0.020 |
Why?
| | Pilot Projects | 1 | 2018 | 1838 | 0.020 |
Why?
| | Receptor, Notch1 | 1 | 2013 | 65 | 0.020 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2012 | 27 | 0.020 |
Why?
| | Retinal Dehydrogenase | 1 | 2012 | 30 | 0.020 |
Why?
| | Anemia, Aplastic | 3 | 1983 | 42 | 0.020 |
Why?
| | Cetuximab | 1 | 2013 | 108 | 0.020 |
Why?
| | Mechlorethamine | 3 | 1982 | 60 | 0.020 |
Why?
| | Phenytoin | 2 | 1962 | 21 | 0.020 |
Why?
| | Pathology, Clinical | 1 | 2012 | 29 | 0.020 |
Why?
| | Ascorbic Acid | 1 | 1994 | 180 | 0.020 |
Why?
| | Individuality | 1 | 1994 | 163 | 0.020 |
Why?
| | Response Elements | 1 | 2012 | 89 | 0.020 |
Why?
| | Benzoates | 1 | 1972 | 49 | 0.020 |
Why?
| | Patient Discharge | 1 | 2018 | 923 | 0.020 |
Why?
| | Epithelial Cells | 1 | 1998 | 1125 | 0.020 |
Why?
| | Iron | 3 | 1989 | 345 | 0.020 |
Why?
| | Rectal Neoplasms | 1 | 1993 | 153 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2012 | 253 | 0.020 |
Why?
| | Flow Cytometry | 3 | 2008 | 1192 | 0.020 |
Why?
| | Coloring Agents | 1 | 2012 | 96 | 0.020 |
Why?
| | Vaccines | 1 | 1997 | 410 | 0.020 |
Why?
| | Tumor Microenvironment | 1 | 2016 | 732 | 0.020 |
Why?
| | Isoenzymes | 1 | 2012 | 299 | 0.020 |
Why?
| | Hawaii | 1 | 1991 | 41 | 0.020 |
Why?
| | Precision Medicine | 1 | 2016 | 444 | 0.020 |
Why?
| | Mice, SCID | 1 | 2012 | 372 | 0.020 |
Why?
| | Gene Silencing | 1 | 2012 | 201 | 0.020 |
Why?
| | Mitosis | 1 | 1992 | 202 | 0.020 |
Why?
| | Sodium | 2 | 1962 | 199 | 0.020 |
Why?
| | Prednisone | 1 | 1972 | 232 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2012 | 270 | 0.020 |
Why?
| | 9,10-Dimethyl-1,2-benzanthracene | 1 | 2010 | 24 | 0.020 |
Why?
| | Melphalan | 3 | 1986 | 41 | 0.020 |
Why?
| | Paclitaxel | 1 | 2012 | 236 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2013 | 374 | 0.020 |
Why?
| | Bacteria | 1 | 1977 | 888 | 0.020 |
Why?
| | Dermatology | 1 | 2012 | 125 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 607 | 0.020 |
Why?
| | Mice, Inbred C57BL | 4 | 2010 | 6043 | 0.020 |
Why?
| | Sex Ratio | 1 | 1990 | 15 | 0.020 |
Why?
| | DNA Repair | 1 | 2013 | 250 | 0.020 |
Why?
| | Megakaryocytes | 2 | 1981 | 35 | 0.020 |
Why?
| | Blotting, Western | 1 | 2013 | 1223 | 0.020 |
Why?
| | Pigmentation | 1 | 2010 | 54 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2010 | 153 | 0.020 |
Why?
| | DNA Primers | 1 | 2011 | 518 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 637 | 0.020 |
Why?
| | Hepatectomy | 2 | 1962 | 258 | 0.020 |
Why?
| | California | 1 | 1991 | 467 | 0.020 |
Why?
| | Penicillin V | 1 | 1989 | 3 | 0.020 |
Why?
| | DNA Damage | 1 | 2013 | 446 | 0.020 |
Why?
| | Body Surface Area | 1 | 2009 | 36 | 0.020 |
Why?
| | Deferoxamine | 1 | 1989 | 26 | 0.020 |
Why?
| | Imidazoles | 1 | 2010 | 252 | 0.020 |
Why?
| | Diagnosis, Differential | 2 | 2012 | 1504 | 0.020 |
Why?
| | Lithium Chloride | 2 | 1986 | 12 | 0.020 |
Why?
| | Circadian Rhythm | 1 | 1994 | 513 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2011 | 763 | 0.020 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2010 | 187 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 1989 | 117 | 0.020 |
Why?
| | Bone Regeneration | 2 | 1986 | 27 | 0.020 |
Why?
| | Mouth | 1 | 1989 | 88 | 0.020 |
Why?
| | Interferon beta-1a | 1 | 2008 | 14 | 0.020 |
Why?
| | Glatiramer Acetate | 1 | 2008 | 18 | 0.020 |
Why?
| | Eye Color | 1 | 1988 | 3 | 0.020 |
Why?
| | Anemia | 2 | 1982 | 177 | 0.020 |
Why?
| | Abdomen | 1 | 2009 | 140 | 0.020 |
Why?
| | Colorado | 2 | 2009 | 4658 | 0.020 |
Why?
| | Temperature | 3 | 1981 | 676 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2009 | 527 | 0.020 |
Why?
| | Cellular Senescence | 1 | 2010 | 227 | 0.020 |
Why?
| | Upper Extremity | 1 | 2009 | 110 | 0.020 |
Why?
| | Cimetidine | 1 | 1988 | 11 | 0.020 |
Why?
| | Chlorides | 2 | 1986 | 137 | 0.020 |
Why?
| | Interferon-beta | 1 | 2008 | 94 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2008 | 167 | 0.020 |
Why?
| | Surgical Procedures, Operative | 1 | 1971 | 274 | 0.020 |
Why?
| | Contusions | 1 | 2007 | 21 | 0.020 |
Why?
| | Nausea | 1 | 2007 | 112 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2007 | 154 | 0.020 |
Why?
| | Leukopenia | 2 | 1991 | 32 | 0.020 |
Why?
| | Molecular Weight | 2 | 1979 | 327 | 0.020 |
Why?
| | Enterobacter aerogenes | 1 | 2006 | 3 | 0.020 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2006 | 20 | 0.020 |
Why?
| | Vaccines, Combined | 2 | 1997 | 49 | 0.020 |
Why?
| | Laparotomy | 1 | 2007 | 116 | 0.020 |
Why?
| | Electric Injuries | 1 | 1986 | 2 | 0.020 |
Why?
| | Hydroxyurea | 2 | 1984 | 34 | 0.020 |
Why?
| | N-Acetylgalactosaminyltransferases | 1 | 2005 | 6 | 0.010 |
Why?
| | MART-1 Antigen | 1 | 2005 | 11 | 0.010 |
Why?
| | Tomography, Emission-Computed | 1 | 1986 | 68 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 856 | 0.010 |
Why?
| | Hemoglobins | 1 | 1988 | 365 | 0.010 |
Why?
| | Metaproterenol | 1 | 1985 | 1 | 0.010 |
Why?
| | Culture Media | 4 | 1977 | 165 | 0.010 |
Why?
| | Reference Standards | 1 | 2006 | 181 | 0.010 |
Why?
| | Liver Neoplasms | 2 | 2006 | 758 | 0.010 |
Why?
| | Extremities | 1 | 2006 | 141 | 0.010 |
Why?
| | Double-Blind Method | 3 | 1998 | 2017 | 0.010 |
Why?
| | Prospective Studies | 4 | 2005 | 7899 | 0.010 |
Why?
| | Wrist Injuries | 1 | 1985 | 23 | 0.010 |
Why?
| | Platelet Count | 2 | 1986 | 92 | 0.010 |
Why?
| | Neoplasm Proteins | 2 | 2005 | 443 | 0.010 |
Why?
| | Fatigue | 1 | 2007 | 349 | 0.010 |
Why?
| | Edetic Acid | 1 | 1985 | 48 | 0.010 |
Why?
| | Accidents, Occupational | 1 | 1985 | 14 | 0.010 |
Why?
| | Antigens, CD | 1 | 2008 | 549 | 0.010 |
Why?
| | Kaplan-Meier Estimate | 1 | 2007 | 921 | 0.010 |
Why?
| | Lower Extremity | 1 | 2009 | 444 | 0.010 |
Why?
| | Erythrocytes | 3 | 1981 | 708 | 0.010 |
Why?
| | Disease Outbreaks | 1 | 1988 | 430 | 0.010 |
Why?
| | Spleen | 2 | 1981 | 517 | 0.010 |
Why?
| | Constriction, Pathologic | 1 | 1985 | 246 | 0.010 |
Why?
| | Blood Platelets | 3 | 1974 | 390 | 0.010 |
Why?
| | Syndrome | 1 | 1985 | 379 | 0.010 |
Why?
| | Epinephrine | 1 | 1985 | 148 | 0.010 |
Why?
| | Dendritic Cells | 1 | 2008 | 502 | 0.010 |
Why?
| | Nucleoproteins | 1 | 1984 | 37 | 0.010 |
Why?
| | Survivors | 1 | 2008 | 502 | 0.010 |
Why?
| | Remission Induction | 2 | 1995 | 306 | 0.010 |
Why?
| | Emergencies | 1 | 1985 | 180 | 0.010 |
Why?
| | Administration, Topical | 1 | 1984 | 153 | 0.010 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2005 | 388 | 0.010 |
Why?
| | Podophyllotoxin | 1 | 1984 | 8 | 0.010 |
Why?
| | Necrosis | 1 | 1985 | 247 | 0.010 |
Why?
| | Pregnancy Trimester, Third | 1 | 2004 | 113 | 0.010 |
Why?
| | Neuropilin-1 | 1 | 2003 | 7 | 0.010 |
Why?
| | Blood Vessels | 1 | 1985 | 175 | 0.010 |
Why?
| | Sex Characteristics | 1 | 2009 | 793 | 0.010 |
Why?
| | Etoposide | 1 | 1984 | 165 | 0.010 |
Why?
| | Liver | 2 | 1962 | 1864 | 0.010 |
Why?
| | Fibula | 1 | 1983 | 40 | 0.010 |
Why?
| | Cell Nucleolus | 1 | 1983 | 19 | 0.010 |
Why?
| | Enterobacter | 1 | 1983 | 8 | 0.010 |
Why?
| | Antibodies, Antinuclear | 1 | 1983 | 67 | 0.010 |
Why?
| | Heart Arrest | 2 | 1984 | 399 | 0.010 |
Why?
| | Busulfan | 1 | 1982 | 15 | 0.010 |
Why?
| | Klebsiella pneumoniae | 1 | 1983 | 46 | 0.010 |
Why?
| | Absorption | 1 | 1982 | 60 | 0.010 |
Why?
| | Cell Nucleus | 2 | 1984 | 612 | 0.010 |
Why?
| | Sodium, Dietary | 1 | 1962 | 38 | 0.010 |
Why?
| | Erythropoiesis | 1 | 1982 | 56 | 0.010 |
Why?
| | Bleomycin | 1 | 1984 | 242 | 0.010 |
Why?
| | Cytoplasm | 1 | 1983 | 267 | 0.010 |
Why?
| | Ultrasonography | 1 | 2006 | 769 | 0.010 |
Why?
| | Ischemia | 1 | 1985 | 416 | 0.010 |
Why?
| | Carcinoma, Small Cell | 1 | 1982 | 172 | 0.010 |
Why?
| | Pain | 1 | 2007 | 781 | 0.010 |
Why?
| | Hypoglycemia | 1 | 2007 | 473 | 0.010 |
Why?
| | Schistosomiasis | 1 | 1982 | 50 | 0.010 |
Why?
| | Transplantation, Autologous | 4 | 1984 | 284 | 0.010 |
Why?
| | Glucose | 1 | 2007 | 1042 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2009 | 3380 | 0.010 |
Why?
| | Choriocarcinoma | 1 | 1981 | 9 | 0.010 |
Why?
| | Glycogen Storage Disease Type I | 1 | 1980 | 9 | 0.010 |
Why?
| | Biopsy | 1 | 2004 | 1083 | 0.010 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2001 | 217 | 0.010 |
Why?
| | Thymidine Kinase | 1 | 2000 | 16 | 0.010 |
Why?
| | Pseudomonas aeruginosa | 1 | 1983 | 361 | 0.010 |
Why?
| | Antibodies, Bacterial | 1 | 1980 | 146 | 0.010 |
Why?
| | Regeneration | 1 | 1962 | 198 | 0.010 |
Why?
| | Doxycycline | 1 | 2000 | 60 | 0.010 |
Why?
| | Luciferases | 1 | 2000 | 152 | 0.010 |
Why?
| | Chromosomes, Human, 4-5 | 1 | 1979 | 2 | 0.010 |
Why?
| | Simplexvirus | 1 | 2000 | 82 | 0.010 |
Why?
| | Anemia, Macrocytic | 1 | 1979 | 4 | 0.010 |
Why?
| | Thrombocytosis | 1 | 1979 | 6 | 0.010 |
Why?
| | Pregnancy | 2 | 2004 | 7153 | 0.010 |
Why?
| | Electrophoresis, Cellulose Acetate | 1 | 1979 | 1 | 0.010 |
Why?
| | Pronase | 1 | 1979 | 5 | 0.010 |
Why?
| | Retinoblastoma Protein | 1 | 2000 | 109 | 0.010 |
Why?
| | Blood Transfusion | 2 | 1974 | 401 | 0.010 |
Why?
| | Deoxyribonucleases | 1 | 1979 | 24 | 0.010 |
Why?
| | Ribonucleases | 1 | 1979 | 49 | 0.010 |
Why?
| | Herpesvirus 4, Human | 1 | 2000 | 169 | 0.010 |
Why?
| | Trypsin | 1 | 1979 | 73 | 0.010 |
Why?
| | Autoantibodies | 2 | 1984 | 1492 | 0.010 |
Why?
| | Plasmids | 1 | 2000 | 371 | 0.010 |
Why?
| | Remission, Spontaneous | 2 | 1977 | 40 | 0.010 |
Why?
| | Fluorescent Antibody Technique | 3 | 1984 | 383 | 0.010 |
Why?
| | Sepsis | 1 | 1985 | 638 | 0.010 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 1979 | 65 | 0.010 |
Why?
| | Hematocrit | 2 | 1977 | 104 | 0.010 |
Why?
| | Bacterial Physiological Phenomena | 1 | 1978 | 60 | 0.010 |
Why?
| | Anemia, Hypochromic | 1 | 1977 | 3 | 0.010 |
Why?
| | Hypocalcemia | 3 | 1984 | 36 | 0.010 |
Why?
| | Nitrogen | 1 | 1979 | 168 | 0.010 |
Why?
| | Species Specificity | 1 | 1979 | 577 | 0.010 |
Why?
| | Transfection | 1 | 2000 | 949 | 0.010 |
Why?
| | Staphylococcus | 1 | 1977 | 74 | 0.010 |
Why?
| | Agar | 1 | 1977 | 11 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1979 | 556 | 0.010 |
Why?
| | Trans-Activators | 1 | 2000 | 402 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 2000 | 677 | 0.010 |
Why?
| | Pneumonia | 1 | 1983 | 647 | 0.010 |
Why?
| | Arthritis, Rheumatoid | 2 | 1983 | 1217 | 0.010 |
Why?
| | Pericardium | 1 | 1976 | 61 | 0.010 |
Why?
| | Groin | 1 | 1995 | 13 | 0.010 |
Why?
| | Phagocytosis | 1 | 1977 | 291 | 0.010 |
Why?
| | Streptococcus pneumoniae | 1 | 1977 | 174 | 0.010 |
Why?
| | Subclavian Vein | 1 | 1995 | 15 | 0.010 |
Why?
| | Blood Protein Electrophoresis | 1 | 1975 | 6 | 0.010 |
Why?
| | Typhoid-Paratyphoid Vaccines | 1 | 1975 | 5 | 0.010 |
Why?
| | Pyrogens | 1 | 1975 | 55 | 0.010 |
Why?
| | Iron Radioisotopes | 1 | 1974 | 2 | 0.010 |
Why?
| | Cobalt Radioisotopes | 1 | 1974 | 7 | 0.010 |
Why?
| | Dialysis | 1 | 1974 | 18 | 0.010 |
Why?
| | Pyelonephritis | 1 | 1974 | 11 | 0.010 |
Why?
| | Hospitals, University | 1 | 1995 | 176 | 0.010 |
Why?
| | Centrifugation | 1 | 1974 | 27 | 0.010 |
Why?
| | Patient Compliance | 2 | 1989 | 617 | 0.010 |
Why?
| | Salmonella | 1 | 1975 | 63 | 0.010 |
Why?
| | Vaccines, Attenuated | 1 | 1995 | 130 | 0.010 |
Why?
| | Skin Physiological Phenomena | 1 | 1994 | 25 | 0.010 |
Why?
| | Photoperiod | 1 | 1994 | 53 | 0.010 |
Why?
| | Child, Preschool | 3 | 1985 | 11737 | 0.010 |
Why?
| | Adrenal Gland Neoplasms | 1 | 1974 | 90 | 0.010 |
Why?
| | Drug Costs | 1 | 1994 | 115 | 0.010 |
Why?
| | Virus Diseases | 1 | 1976 | 218 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 1981 | 2026 | 0.010 |
Why?
| | Asthma | 1 | 1985 | 1918 | 0.010 |
Why?
| | Procarbazine | 1 | 1972 | 9 | 0.010 |
Why?
| | Hydrocortisone | 1 | 1975 | 311 | 0.010 |
Why?
| | Diseases in Twins | 1 | 1973 | 159 | 0.010 |
Why?
| | Multiple Myeloma | 1 | 1974 | 288 | 0.010 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 1972 | 123 | 0.010 |
Why?
| | Drug Combinations | 1 | 1972 | 372 | 0.010 |
Why?
| | Doxorubicin | 2 | 1984 | 381 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2000 | 2621 | 0.010 |
Why?
| | Length of Stay | 1 | 1995 | 1279 | 0.000 |
Why?
| | Arm | 2 | 1985 | 109 | 0.000 |
Why?
| | Taurodeoxycholic Acid | 1 | 1989 | 2 | 0.000 |
Why?
| | Placebos | 1 | 1989 | 195 | 0.000 |
Why?
| | Ferritins | 1 | 1989 | 66 | 0.000 |
Why?
| | Perfusion | 1 | 1970 | 242 | 0.000 |
Why?
| | Mouth Mucosa | 1 | 1989 | 91 | 0.000 |
Why?
| | Debridement | 1 | 1989 | 91 | 0.000 |
Why?
| | Antibody Formation | 1 | 1970 | 297 | 0.000 |
Why?
| | Bone Marrow Examination | 2 | 1979 | 5 | 0.000 |
Why?
| | Skin | 1 | 1994 | 774 | 0.000 |
Why?
| | Wounds and Injuries | 1 | 1995 | 941 | 0.000 |
Why?
| | Scalp | 1 | 1986 | 39 | 0.000 |
Why?
| | Peak Expiratory Flow Rate | 1 | 1985 | 25 | 0.000 |
Why?
| | Prostaglandins E | 1 | 1985 | 45 | 0.000 |
Why?
| | Saudi Arabia | 1 | 1985 | 6 | 0.000 |
Why?
| | Lactoferrin | 1 | 1985 | 38 | 0.000 |
Why?
| | Immunodiffusion | 1 | 1984 | 12 | 0.000 |
Why?
| | Polysaccharides, Bacterial | 1 | 1985 | 68 | 0.000 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 1984 | 53 | 0.000 |
Why?
| | Angiography | 1 | 1985 | 207 | 0.000 |
Why?
| | Antigen-Antibody Complex | 1 | 1984 | 72 | 0.000 |
Why?
| | Teniposide | 1 | 1984 | 3 | 0.000 |
Why?
| | Chromosomes, Human, 21-22 and Y | 1 | 1984 | 3 | 0.000 |
Why?
| | Aerosols | 1 | 1985 | 180 | 0.000 |
Why?
| | Tissue Preservation | 1 | 1984 | 12 | 0.000 |
Why?
| | Daunorubicin | 1 | 1984 | 25 | 0.000 |
Why?
| | Melanoma-Specific Antigens | 1 | 1983 | 5 | 0.000 |
Why?
| | False Negative Reactions | 1 | 1983 | 61 | 0.000 |
Why?
| | Syncope | 1 | 1984 | 58 | 0.000 |
Why?
| | Rats | 2 | 1962 | 5610 | 0.000 |
Why?
| | Arteries | 1 | 1985 | 261 | 0.000 |
Why?
| | Cell Line | 2 | 1983 | 2897 | 0.000 |
Why?
| | Postoperative Complications | 1 | 1995 | 2887 | 0.000 |
Why?
| | Regional Blood Flow | 1 | 1985 | 504 | 0.000 |
Why?
| | Phosphates | 1 | 1984 | 178 | 0.000 |
Why?
| | Lomustine | 1 | 1982 | 14 | 0.000 |
Why?
| | Heterozygote | 1 | 1983 | 311 | 0.000 |
Why?
| | Egypt | 1 | 1982 | 12 | 0.000 |
Why?
| | Fever | 1 | 1984 | 310 | 0.000 |
Why?
| | Heart Rate | 1 | 1985 | 844 | 0.000 |
Why?
| | Cytotoxicity, Immunologic | 1 | 1981 | 222 | 0.000 |
Why?
| | Mice, Inbred Strains | 1 | 1981 | 408 | 0.000 |
Why?
| | Tachycardia | 1 | 1981 | 57 | 0.000 |
Why?
| | Cell Separation | 1 | 1981 | 311 | 0.000 |
Why?
| | Histocompatibility Antigens Class II | 1 | 1981 | 367 | 0.000 |
Why?
| | Fanconi Anemia | 1 | 1979 | 11 | 0.000 |
Why?
| | Blood Cells | 1 | 1979 | 38 | 0.000 |
Why?
| | Blood Pressure | 1 | 1985 | 1755 | 0.000 |
Why?
| | Complement System Proteins | 1 | 1981 | 312 | 0.000 |
Why?
| | Electrocardiography | 1 | 1981 | 630 | 0.000 |
Why?
| | Cold Temperature | 1 | 1979 | 201 | 0.000 |
Why?
| | Blood | 1 | 1977 | 110 | 0.000 |
Why?
| | Pericardial Effusion | 1 | 1976 | 21 | 0.000 |
Why?
| | Autopsy | 1 | 1976 | 98 | 0.000 |
Why?
| | Cell Count | 1 | 1977 | 323 | 0.000 |
Why?
| | DNA | 1 | 1983 | 1457 | 0.000 |
Why?
| | Kidney Failure, Chronic | 1 | 1982 | 600 | 0.000 |
Why?
| | Alpha-Globulins | 1 | 1975 | 20 | 0.000 |
Why?
| | Cytogenetics | 1 | 1973 | 10 | 0.000 |
Why?
| | Recurrence | 1 | 1977 | 1114 | 0.000 |
Why?
| | Periodicity | 1 | 1973 | 56 | 0.000 |
Why?
| | Muramidase | 1 | 1973 | 66 | 0.000 |
Why?
| | Chronic Disease | 1 | 1977 | 1824 | 0.000 |
Why?
| | Leg | 1 | 1972 | 240 | 0.000 |
Why?
| | Splenectomy | 1 | 1970 | 61 | 0.000 |
Why?
| | Immunity | 1 | 1970 | 138 | 0.000 |
Why?
| | Immunization | 1 | 1970 | 404 | 0.000 |
Why?
| | Swine | 1 | 1970 | 837 | 0.000 |
Why?
| | Sheep | 1 | 1970 | 885 | 0.000 |
Why?
|
|
Robinson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|